Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia. Issue 2 (3rd April 2021)

• Record Type: Journal Article
• Authors: Shindo, Takero; Ureshino, Hiroshi; Kojima, Hiroto; Tanaka, Hidenori; Kimura, Shinya
• Is Part Of: Immunological medicine. Volume 44:Issue 2(2021)
• Page Start: 61
• Page End: 68
• Publication Date: 2021-04-03
• Subjects: Chronic myeloid leukemia (CML) -- tyrosine kinase inhibitor (TKI) -- antitumor immunity -- natural killer (NK) cell -- killer immunoglobulin-like receptor (KIR); Immune System Phenomena; Immune System Diseases; Immunology -- Periodicals; Immunology; Periodical; Periodicals; Electronic journals; 571.96
• DOI: 10.1080/25785826.2020.1796062
• Languages: English
• ISSNs: 2578-5826

Abstract

Abstract: The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) markedly improved the prognosis of patients with chronic myeloid leukemia (CML). Approximately 50% of patients who achieve deep molecular response (DMR) remain in treatment-free remission (TFR) even after discontinuation of TKIs. Although TKIs may achieve clinical "cure" after TKI treatment for specific periods, there are no reliable biomarkers for predicting the response to TKIs and the probability of TFR in CML. An increase in natural killer (NK) cells in the peripheral blood of TKI-treated CML patients is correlated with better outcomes, suggesting that TKIs induce antitumor NK cell immunity against CML cells. Killer immunoglobulin-like receptors (KIRs) are highly polymorphic NK cell receptors that play important roles in the regulation of immune responses. The identification of allelic polymorphisms of KIRs by next-generation sequencing uncovered novel aspects of KIRs. Here we summarize the current knowledge of the genetic and immunological aspects of KIRs and discuss the association between allelic polymorphisms of KIRs and TKI-treated CML.